- Home
- DRIO vs XFOR Comparison
DRIO vs XFOR Comparison
Compare DRIO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRIO
- XFOR
- Stock Information
- Founded
- DRIO 2011
- XFOR 2014
- Country
- DRIO United States
- XFOR United States
- Employees
- DRIO N/A
- XFOR N/A
- Industry
- DRIO Medical/Dental Instruments
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DRIO Health Care
- XFOR Health Care
- Exchange
- DRIO Nasdaq
- XFOR Nasdaq
- Market Cap
- DRIO 87.0M
- XFOR 84.3M
- IPO Year
- DRIO N/A
- XFOR N/A
- Fundamental
- Price
- DRIO $15.01
- XFOR $3.13
- Analyst Decision
- DRIO Strong Buy
- XFOR Strong Buy
- Analyst Count
- DRIO 2
- XFOR 3
- Target Price
- DRIO $50.00
- XFOR $34.17
- AVG Volume (30 Days)
- DRIO 143.9K
- XFOR 349.0K
- Earning Date
- DRIO 11-06-2025
- XFOR 11-12-2025
- Dividend Yield
- DRIO N/A
- XFOR N/A
- EPS Growth
- DRIO N/A
- XFOR N/A
- EPS
- DRIO N/A
- XFOR N/A
- Revenue
- DRIO $27,148,000.00
- XFOR $32,774,000.00
- Revenue This Year
- DRIO N/A
- XFOR $1,307.51
- Revenue Next Year
- DRIO $59.84
- XFOR N/A
- P/E Ratio
- DRIO N/A
- XFOR N/A
- Revenue Growth
- DRIO 41.79
- XFOR 5721.31
- 52 Week Low
- DRIO $5.94
- XFOR $1.35
- 52 Week High
- DRIO $31.00
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- DRIO 58.22
- XFOR 48.22
- Support Level
- DRIO $12.22
- XFOR $2.80
- Resistance Level
- DRIO $16.50
- XFOR $3.21
- Average True Range (ATR)
- DRIO 1.30
- XFOR 0.22
- MACD
- DRIO -0.47
- XFOR -0.04
- Stochastic Oscillator
- DRIO 48.01
- XFOR 38.37
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.